| Event . | Adagrasib monotherapy (N=116) . |
|---|---|
| TRAEs leading to dose reduction, n (%) | 60 (52%) |
| GI-related TRAEsb | 23 (20%) |
| ALT increase | 12 (10%) |
| Fatigue | 11 (9%) |
| AST increase | 7 (6%) |
| TRAEs leading to dose interruption, n (%) | 71 (61%) |
| GI-related TRAEsb | 26 (22%) |
| Fatigue | 14 (12%) |
| ALT increase | 11 (9%) |
| AST increase | 10 (9%) |
| TRAEs leading to discontinuation, n (%) | 8 (7%) |
| Ejection fraction decrease | 2 (2%) |
| Transaminase increase | 1 (1%) |
| Hypotension | 1 (1%) |
| Pyrexia | 1 (1%) |
| Unknown | 3 (3%) |
| Event . | Adagrasib monotherapy (N=116) . |
|---|---|
| TRAEs leading to dose reduction, n (%) | 60 (52%) |
| GI-related TRAEsb | 23 (20%) |
| ALT increase | 12 (10%) |
| Fatigue | 11 (9%) |
| AST increase | 7 (6%) |
| TRAEs leading to dose interruption, n (%) | 71 (61%) |
| GI-related TRAEsb | 26 (22%) |
| Fatigue | 14 (12%) |
| ALT increase | 11 (9%) |
| AST increase | 10 (9%) |
| TRAEs leading to discontinuation, n (%) | 8 (7%) |
| Ejection fraction decrease | 2 (2%) |
| Transaminase increase | 1 (1%) |
| Hypotension | 1 (1%) |
| Pyrexia | 1 (1%) |
| Unknown | 3 (3%) |
aDose reductions and interruptions shown for only the most commonly occurring TRAEs (GI related, ALT/AST increase, and fatigue).
bMostly diarrhea, nausea, or vomiting. Some patients experienced abdominal pain (n = 1), dyspepsia (n = 1), or pancreatitis (n = 1) that led to dose reductions, and abdominal pain (n = 2), abdominal distension (n = 1), or pancreatitis (n = 1) that led to dose interruptions.
Adapted from Jänne PA et al7, with permission from Massachusetts Medical Society (the full list is available in Supplementary Table S4).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal; TRAE, treatment-related adverse event.
| Event . | Adagrasib monotherapy (N=116) . |
|---|---|
| TRAEs leading to dose reduction, n (%) | 60 (52%) |
| GI-related TRAEsb | 23 (20%) |
| ALT increase | 12 (10%) |
| Fatigue | 11 (9%) |
| AST increase | 7 (6%) |
| TRAEs leading to dose interruption, n (%) | 71 (61%) |
| GI-related TRAEsb | 26 (22%) |
| Fatigue | 14 (12%) |
| ALT increase | 11 (9%) |
| AST increase | 10 (9%) |
| TRAEs leading to discontinuation, n (%) | 8 (7%) |
| Ejection fraction decrease | 2 (2%) |
| Transaminase increase | 1 (1%) |
| Hypotension | 1 (1%) |
| Pyrexia | 1 (1%) |
| Unknown | 3 (3%) |
| Event . | Adagrasib monotherapy (N=116) . |
|---|---|
| TRAEs leading to dose reduction, n (%) | 60 (52%) |
| GI-related TRAEsb | 23 (20%) |
| ALT increase | 12 (10%) |
| Fatigue | 11 (9%) |
| AST increase | 7 (6%) |
| TRAEs leading to dose interruption, n (%) | 71 (61%) |
| GI-related TRAEsb | 26 (22%) |
| Fatigue | 14 (12%) |
| ALT increase | 11 (9%) |
| AST increase | 10 (9%) |
| TRAEs leading to discontinuation, n (%) | 8 (7%) |
| Ejection fraction decrease | 2 (2%) |
| Transaminase increase | 1 (1%) |
| Hypotension | 1 (1%) |
| Pyrexia | 1 (1%) |
| Unknown | 3 (3%) |
aDose reductions and interruptions shown for only the most commonly occurring TRAEs (GI related, ALT/AST increase, and fatigue).
bMostly diarrhea, nausea, or vomiting. Some patients experienced abdominal pain (n = 1), dyspepsia (n = 1), or pancreatitis (n = 1) that led to dose reductions, and abdominal pain (n = 2), abdominal distension (n = 1), or pancreatitis (n = 1) that led to dose interruptions.
Adapted from Jänne PA et al7, with permission from Massachusetts Medical Society (the full list is available in Supplementary Table S4).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal; TRAE, treatment-related adverse event.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
